



JFL LIFE SCIENCES LIMITED

Date: November 11, 2025

To,
The Manager,
Listing Department
The National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051

Dear Sir/Madam,

NSE Symbol: JFL LIFE; ISIN: INE0LA901015

Subject: Outcome of Board Meeting held on Tuesday, November 11, 2025

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that a meeting of the Board of Directors of JFL Life Sciences Limited ("the Company") has been held on Tuesday, November 11, 2025, at 02:00 P.M. which **concluded at 03:25 PM** and Board has inter alia considered and approved the Standalone Un-audited financial results for the quarter & half-year ended September 30, 2025. A copy of the said unaudited financial results along with the Limited Review Report are enclosed herewith in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

Thanking You

Yours Truly,
For JFL LIFE SCIENCES LIMITED

SMIRAL ASHWINKUMAR PATEL

Managing director
DIN: 00769486

Encl: A/a

Independent Auditor's Review Report on Unaudited Quarterly Financial Results and Year to Date Results of JFL LIFE SCIENCES LIMITED pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)


To
The Board of Directors
JFL LIFE SCIENCES LIMITED
309, Satyam Mall, Opp. Saman Complex,
Nr. Vishweshwar Mahadev Mandir, Settelite,
Ahmedabad, Gujrat, India, 380015

1. We have reviewed the accompanying statement of unaudited financial results of **JFL Life Sciences Limited** (the 'Company') for the quarter ended September 30, 2025 and the year-to-date results for the period 01 April 2025 to 30 September 2025, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ("Listing Regulations").
2. The Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 ("the Act") as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with the presentation and disclosure requirement of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India.

A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with recognition and measurement principles laid down in Ind AS 34, Prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirement of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **Doshi Doshi & Co,**
Chartered Accountants
Firm Registration No.: 153683W


Chintan R. Doshi
Partner
Membership No.: 158931
UDIN: 25158931BMIGN03419



Place: Ahmedabad
Date: November 11, 2025

JFL Life Sciences Limited

CIN : L24230GJ2010PLC060417

Reg Office :- 309, SATYAM MALL, OPP. SAMAN COMPLEX, NR. VISHWESHWAR MAHADEV MANDIR, SETTELITE, AHMEDABAD 380015
Tele No. +91-93772 95575, Email id :- info@jfllifesciences.com, www.jfllifesciences.com

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH September, 2025

(Rs. In Lakhs)

Sr. No.	PARTICULARS.	Quarter Ended on			Half year ended		Year Ended on
		30.09.2025 (Unaudited)	30.06.2025 (Unaudited)	30.09.2024 (Unaudited)	30.09.2025 (Unaudited)	30.09.2024 (Unaudited)	31.03.2025 (Audited)
	INCOMES						
I	Revenue from Operations	2,990.65	1,158.54	3,951.10	4,149.19	4,905.59	8,204.23
II	Other Income	1.20	0.28	0.04	1.48	0.44	1.01
III	Total Income (I + II)	2,991.85	1,158.82	3,951.14	4,150.67	4,906.03	8,205.24
IV	EXPENSES						
(a)	Cost of materials consumed	2,664.99	759.23	3,636.91	3,424.22	4,281.90	6,677.44
(b)	Changes of Inventories of Finished Goods, Work in Progress, Stock in Trade.	(13.31)	8.10	33.42	(5.21)	(67.56)	(66.30)
(c)	Employee benefits expense	26.45	23.21	36.88	49.66	96.30	101.09
(d)	Finance Cost	44.26	24.48	27.22	68.74	53.52	108.12
(e)	Depreciation and Amortisation Expenses	26.83	26.40	23.90	53.23	47.81	99.25
(f)	Other Expenses	21.02	174.65	3.21	195.67	48.63	672.10
	TOTAL EXPENSES (IV (a to f))	2,770.24	1,016.06	3,761.54	3,786.31	4,460.61	7,591.70
V	Profit/(Loss) before Exceptional Items and Tax. (III-IV)	221.61	142.76	189.61	364.36	445.42	613.54
VI	Exceptional Items, & Extraordinary Item	-	-	-	-	-	-
VII	Profit/(Loss) Before Tax. (V-VI)	221.60	142.76	189.60	364.36	445.42	613.54
VIII	TAX EXPENSES						
(a)	Current Tax	70.84	22.59	46.44	93.43	109.15	152.78
(b)	Deferred Tax	(46.66)	45.54	(1.69)	(1.12)	2.96	44.90
	Total Tax Expenses.	24.18	68.13	44.75	92.31	112.11	197.69
IX	NET PROFIT / (LOSS) FOR THE PERIOD	197.43	74.63	144.85	272.06	336.27	415.86
X	Items that will not be reclassified to profit or loss						
(i)	Re-measurement gains on defined benefit plans	(0.76)	0.09	-	(0.67)	-	0.36
	Other comprehensive income for the year, net of tax	(0.76)	0.09	-	(0.67)	-	0.36
	Total comprehensive income for the year	198.19	74.54	144.85	272.73	336.27	415.50
XI	Paid up Equity Share Capital (Amount in lacs) Rs. 10 Face value per share	329.95 Rs. 10/-	329.95 Rs. 10/-	109.98 Rs. 10/-	329.95 Rs. 10/-	109.98 Rs. 10/-	329.95 Rs. 10/-
XII	Earning Per Share (In Rupees) from						
(i)	Basic.	0.60	0.23	1.32	0.83	3.06	1.26
(ii)	Diluted.	0.60	0.23	1.32	0.83	3.06	1.26

NOTES:

- These financial result were reviewed by the Board of Directors and Audit Committee thereafter have been approved by the board of directors at its meeting held on November 11th, 2025. The Statutory Auditors have carried out Review of the Unaudited Financial Result for the Quarter ended on 30th Sept, 2025.
- Financial results for the periods presented have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (as amended from time to time) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable and in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended.
- Company has only one reportable segment - Pharmaceuticals Manufacturing.
- Figures for the previous period have been regrouped/ rearranged/ reclassified wherever considered necessary to correspond with the current period's classification/group's disclosure.

For JFL Life Sciences Limited

Smiral A. Patel
Managing Director
DIN : 00769486
Date: November 11, 2025
Place : Ahmedabad



Registered Office Address : 309, Satyam Mall, Opp. Saman Complex, Nr. Vishweshwar Mahadev Mandir, Satellite, Ahmedabad-380015.

Unit-I : 615, G.I.D.C. Estate Kerala, Bavla, Ahmedabad, Gujarat-382220.

Unit-II : 406,407, G.I.D.C. Kerala, Bavla, Ahmedabad, Gujarat-382220.

CIN : L24230GJ2010PLC060417 | Contact No.: 9377295575 | Email : info@jfllifesciences.com | Website : www.jfllifesciences.com

JFL Life Sciences Limited

CIN : L24230GJ2010PLC060417

Reg Office :- 309, SATYAM MALL, OPP. SAMAN COMPLEX, NR. VISHWESHWAR MAHADEV MANDIR, SETTELITE, AHMEDABAD 380015
Tele No. +91-93772 95575, Email id :- info@jfllifesciences.com, www.jfllifesciences.com

STATEMENT OF ASSETS AND LIABILITIES AS AT 30TH September, 2025

PARTICULARS.	AS AT 30 September 2025	AS AT 31 Mar 2025
	UNAUDITED	AUDITED
Assets		
Non-current assets		
Property, plant and equipment	919.56	961.46
Right of Use Assets	260.46	262.18
Non - Current Financial Assets		
(i) Other financial assets	17.36	17.36
Deferred tax Assets (Net)	-	-
Other Non Current Assets	-	-
Total Non-Current Assets	1,197.38	1,241.00
Current assets		
Inventories	3,323.55	2,324.11
Current Financial assets		
(i) Trade receivables	3,655.68	3,494.51
(ii) Cash and cash equivalents	159.28	3.39
(iii) Bank balances other than cash and cash equivalents	59.91	3.00
(iv) Other financial assets	0.57	0.16
Other current assets	161.60	125.23
Total Current Assets	7,360.56	5,950.40
Total Assets	8,557.95	7,191.40
Equity and liabilities		
Equity		
Equity share capital	3,299.53	3,299.53
Other equity	918.60	646.01
Total equity	4,218.12	3,945.54
Liabilities		
Non-current liabilities		
Non - Current Financial liabilities		
i. Borrowings	27.00	37.98
Provisions	13.73	13.00
Deferred tax liabilities (Net)	31.61	32.73
Total Non-Current Liabilities	72.35	83.71
Current liabilities		
Current Financial liabilities		
i. Borrowings	1,093.41	1,021.04
ii. Trade payables		
- Total outstanding dues of micro and small enterprises	-	-
- Total outstanding dues of creditors other than micro and small enterprises	2,826.98	1,775.71
Other Current liabilities	26.99	138.68
Provisions	8.52	8.48
Current tax liabilities (net)	311.58	218.23
Total current liabilities	4,267.47	3,162.15
Total liabilities	4,339.82	3,245.86
Total equity and liabilities	8,557.95	7,191.40

For JFL Life Sciences Limited

Smiral A. Patel
Managing Director
DIN : 00769486

Date: November 11, 2025

Place: Ahmedabad



Registered Office Address : 309, Satyam Mall, Opp. Saman Complex, Nr. Vishweshwar Mahadev Mandir, Satellite, Ahmedabad-380015.

Unit-I : 615, G.I.D.C. Estate Kerala, Bavla, Ahmedabad, Gujarat-382220.

Unit-II : 406,407, G.I.D.C. Kerala, Bavla, Ahmedabad, Gujarat-382220.

CIN : L24230GJ2010PLC060417 | Contact No.: 9377295575 | Email : info@jfllifesciences.com | Website : www.jfllifesciences.com

JFL Life Sciences Limited

CIN : L24230GJ2010PLC060417

Reg Office :- 309, SATYAM MALL, OPP. SAMAN COMPLEX, NR. VISHWESHWAR MAHADEV MANDIR, SETTELITE, AHMEDABAD 380015

Tele No. +91-93772 95575, Email id :- info@jfllifesciences.com, www.jfllifesciences.com

UNAUDITED STATEMENT OF CASH FLOW FOR THE HALF YEAR ENDED 30TH September, 2025

(Rs.In Lakhs)

Particulars	For the period ended 31 September 2025	For the Year ended 31 March 2025
	UNAUDITED	AUDITED
A. CASH FLOW FROM OPERATING ACTIVITIES		
Profit before tax	365.05	613.19
Finance cost	68.74	108.12
Depreciation and amortisation income	53.23	99.25
Interest income	(0.58)	(0.78)
Operating profit before working capital changes	486.44	819.78
Movements in working capital:		
Adjusted for (Increase)/Decrease in operating assets		
Long-Term Loans and advances	-	(2.09)
Inventories	(999.43)	(740.78)
Trade Receivables	(161.16)	(1,011.36)
Other Current Financial Assets	(0.40)	2.57
Other Current Assets	(36.36)	(32.95)
Adjusted for Increase/(Decrease) in operating liabilities:		
Trade Payables	1,051.28	577.37
Provisions	0.61	4.91
Other Current Liabilities	(111.70)	131.78
Cash generated (used in)/from operations	229.27	(250.77)
Income tax paid	(0.08)	(102.39)
Net cash flow generated (used in)/from operating activities (A)	229.19	(353.16)
B. CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of property plant & equipment and intangible asset	(9.61)	(39.52)
Interest received	0.58	0.78
(Bought) / Matured fixed deposits	(56.91)	37.70
Net cash flow from/(used in) investing activities (B)	(65.94)	(1.04)
C. CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds / (Repayment) of long and short-term borrowings	61.39	489.79
Dividend paid during the year	-	(27.50)
Finance cost	(68.74)	(108.12)
Net cash flow from / (used in) financing activities (C)	(7.35)	354.17
Net increase / (decrease) in cash and cash equivalents (A+B+C)	155.89	(0.02)
Cash and cash equivalents at the beginning of the year	3.39	3.41
Cash and cash equivalents at the end of the year	159.28	3.39

For JFL Life Sciences Limited

Smiral A. Patel
Managing Director
DIN : 00769486

Date: November 11, 2025

Place : Ahmedabad



Registered Office Address : 309, Satyam Mall, Opp. Saman Complex, Nr.Vishweshwar Mahadev Mandir, Satellite, Ahmedabad-380015.

Unit-I : 615, G.I.D.C. Estate Kerala, Bavla, Ahmedabad, Gujarat-382220.

Unit-II : 406,407, G.I.D.C. Kerala, Bavla, Ahmedabad, Gujarat-382220.

CIN : L24230GJ2010PLC060417 | Contact No.: 9377295575 | Email : info@jfllifesciences.com | Website : www.jfllifesciences.com